- Bexicaserin achieved an general median seizure discount of 57.7% in countable motor seizures over an approximate 9-month remedy interval
- Favorable security and tolerability outcomes proceed to be noticed
- Knowledge to be introduced on the fifteenth European Epilepsy Congress in Rome, Italy
- Full 12-month OLE dataset anticipated early subsequent 12 months
LA JOLLA, Calif.–(BUSINESS WIRE)–Longboard Prescription drugs, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical firm targeted on creating novel, transformative medicines for neurological ailments, at present introduced constructive interim outcomes from its ongoing 52-week open-label extension of the PACIFIC Examine evaluating bexicaserin (LP352) in individuals ages 12-65 years previous with Developmental and Epileptic Encephalopathies (DEEs).
We’re thrilled that bexicaserin is constant to display a sustained, sturdy response in seizure discount and a positive security and tolerability profile throughout a broad vary of DEE sufferers. These knowledge present additional help to bexicaserin’s potential to supply a extremely differentiated and best-in-class profile, said Dr. Randall Kaye, Longboard’s Chief Medical Officer.
Given the great unmet want in sufferers dwelling with DEEs, we’re dedicated to quickly advancing the event of bexicaserin. We count on to offer a full evaluation of individuals with 12-month knowledge early subsequent 12 months as they full the OLE Examine and transition to our Expanded Entry Program, Dr. Kaye continued. With Breakthrough Remedy designation granted, we stay on monitor to provoke our world Part 3 program for bexicaserin later this 12 months.
PACIFIC OLE Examine Interim Evaluation:
The PACIFIC OLE Examine is a 52-week Part 2, open-label, long-term security research of bexicaserin in individuals with a spread of DEEs together with Dravet syndrome (n=3), Lennox-Gastaut syndrome (n=20) and DEE Different (n=18), who accomplished the PACIFIC Examine (n=41). The research goals are to analyze the security and tolerability of a number of doses of bexicaserin in individuals with DEEs, and to investigate the impact of bexicaserin on the frequency of noticed countable motor seizures and different seizure varieties. The interim evaluation was performed when individuals reached the approximate 9-month level within the OLE Examine.
Abstract of Efficacy Outcomes:
The median change in countable motor seizure frequency for individuals within the OLE Examine over an approximate 9-month remedy interval was a lower of 57.7% (n=40) from their baseline getting into the PACIFIC Examine.
The median change in countable motor seizure frequency from baseline for:
- individuals randomized to the bexicaserin-treated group within the PACIFIC Examine was a lower of 58.2% (n=31)
- individuals randomized to the placebo group within the PACIFIC Examine that transitioned to bexicaserin within the OLE was a lower of 57.3% (n=9)
Abstract of Security and Tolerability Outcomes:
Continued favorable security and tolerability outcomes had been noticed on this research. 100% of PACIFIC Examine completers elected to enroll within the OLE with 92.7% (38 out of 41) remaining within the ongoing open-label research. By means of the approximate nine-month interval, one participant discontinued because of the opposed occasion (AE) of lethargy and two individuals discontinued by withdrawal of consent or different (relocation). The most typical remedy emergent AEs within the general group (n=41) occurring in >5% of individuals had been higher respiratory tract infections, COVID-19, pneumonia, sinusitis, decreased urge for food, pyrexia, and weight lower.
ABOUT THE PACIFIC STUDY AND THE OLE STUDY
The PACIFIC Examine is a Part 1b/2a double-blind, placebo-controlled scientific trial to evaluate the security, tolerability, efficacy and pharmacokinetics of bexicaserin (LP352) in 52 individuals between the ages of 12 and 65 years previous with DEEs at 34 websites throughout america and Australia. Following a 5-week screening interval and baseline evaluations, research individuals initiated a dose titration over a 15-day interval and subsequently continued on the very best tolerated dose all through the upkeep interval of 60 days. Following the upkeep interval, individuals had been then titrated down, and eligible individuals got the chance to enroll within the 52-week open-label extension research.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Prescription drugs, Inc. is a clinical-stage biopharmaceutical firm targeted on creating novel, transformative medicines for neurological ailments. Longboard is working to advance a portfolio of centrally performing product candidates designed to be extremely selective for particular G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based mostly on greater than 20 years of GPCR analysis. Longboard plans to advance bexicaserin (LP352), an oral, centrally performing 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no noticed affect on 5-HT2B and 5-HT2A receptor subtypes, into a world Part 3 program. The FDA has granted Breakthrough Remedy designation for bexicaserin for the remedy of seizures related to Developmental and Epileptic Encephalopathies (DEEs) for sufferers two years of age and older. Earlier this 12 months, Longboard reported constructive topline knowledge from a Part 1b/2a scientific trial (the PACIFIC Examine) evaluating bexicaserin in individuals with DEEs. Longboard can also be evaluating LP659, an oral, centrally performing, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in growth for the potential remedy of uncommon neuroinflammatory situations. Longboard not too long ago accomplished a Part 1 single-ascending dose (SAD) scientific trial for LP659 in wholesome volunteers.
Bexicaserin and LP659 are investigational compounds that aren’t accepted for advertising and marketing by the U.S. Meals and Drug Administration (FDA) or every other regulatory authority.
FORWARD-LOOKING STATEMENTS
Sure statements on this press launch are forward-looking statements that contain plenty of dangers and uncertainties. In some instances, you may establish forward-looking statements by phrases similar to to be introduced, count on, focus, potential, dedicated to, on monitor to, goal, working to, designed to, plans or the adverse, plural or different tenses of those phrases, references to future dates or time durations, or different comparable language, and so they could embrace, with out limitation, statements concerning the following: Longboard’s product candidates (together with their potential and design), scientific and preclinical applications (together with initiation of scientific trials, knowledge from scientific trials, and individuals’ enrollment in or completion of research), plans, focus and work. For such statements, Longboard claims the safety of the Personal Securities Litigation Reform Act of 1995. Precise occasions or outcomes could differ materially from Longboard’s expectations. Components that might trigger precise outcomes to vary materially from these said or implied by Longboard’s forward-looking statements embrace, however usually are not restricted to, the next: topline or interim knowledge could not precisely replicate the entire outcomes of a specific research or trial, and remaining knowledge could differ materially from topline or interim knowledge; PACIFIC Examine individuals’ diagnoses are as of time of screening and are topic to alter; outcomes of scientific trials and different research are topic to totally different interpretations and is probably not predictive of future outcomes; dangers associated to Longboard’s restricted working historical past, monetary place and want for extra capital; Longboard will want extra managerial and monetary sources to advance all of its applications, and also you and others could not agree with the way Longboard allocates its sources; dangers associated to the event and commercialization of Longboard’s product candidates; Longboard’s product candidates are within the early to center phases of a prolonged analysis and growth course of, the timing, method and consequence of analysis, growth and regulatory assessment is unsure, and Longboard’s product candidates could not advance in analysis or growth or be accepted for advertising and marketing; the usual for Breakthrough Remedy designation will not be the identical as the usual for drug approval, the scientific proof supporting Breakthrough Remedy designation is preliminary, and never all medication designated as Breakthrough Therapies finally can be proven to have substantial enchancment over out there therapies; the FDA could later determine to rescind a Breakthrough Remedy designation if it determines the designation is now not supported by subsequent knowledge; enrolling individuals in Longboard’s ongoing and meant scientific trials is aggressive and difficult; dangers associated to surprising or unfavorable new knowledge; nonclinical and scientific knowledge is voluminous and detailed, and regulatory companies could interpret or weigh the significance of information in a different way and attain totally different conclusions than Longboard or others, request extra data, have extra suggestions or change their steerage or necessities earlier than or after approval; macroeconomic occasions and their affect on Longboard’s scientific trials and operations, the operations of Longboard’s suppliers, companions, collaborators, and licensees, and capital markets; dangers associated to counting on licenses or collaborative preparations; different dangers associated to Longboard’s dependence on third events; competitors; product legal responsibility or different litigation or disagreements with others; authorities and third-party payor actions, together with regarding reimbursement and pricing; dangers associated to regulatory compliance; and dangers associated to Longboard’s and third events’ mental property rights. Further elements that might trigger precise outcomes to vary materially from these said or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Trade Fee (SEC). These forward-looking statements characterize Longboard’s judgment as of the time of this launch. Longboard disclaims any intent or obligation to replace these forward-looking statements, aside from as could also be required underneath relevant regulation.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240908536509/en/
CORPORATE CONTACT:
Megan E. Knight
VP, Head of Investor Relations
IR@longboardpharma.com
858.789.9283
Supply: Longboard Prescription drugs, Inc.
